Parasitic helminths and protozoa: Treasure boxes of disease modifying anti-rheumatic drugs

被引:0
|
作者
Osada, Yoshio [1 ]
Shimizu, Shoichi [1 ]
Morita, Kentaro [1 ]
机构
[1] Univ Occupat & Environm Hlth, Dept Immunol & Parasitol, 1-1 Iseigaoka,Yahatanishi Ku, Kitakyushu 8078555, Japan
关键词
Parasite; Helminth; Protozoa; Immunomodulation; Schistosoma; Trichinella; Plasmodium; DMARD; Th17; Cytokine; Microbiota; Collagen; Adjuvant; COLLAGEN-INDUCED ARTHRITIS; SCHISTOSOMA-MANSONI INFECTION; AMELIORATES JOINT DISEASE; TUMOR-NECROSIS-FACTOR; RHEUMATOID-ARTHRITIS; AUTOIMMUNE ARTHRITIS; ADJUVANT ARTHRITIS; BONE EROSION; TNF-ALPHA; B-CELLS;
D O I
10.1016/j.parint.2024.103000
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Parasites generally survive in their hosts by employing various immunomodulation and immune evasion mechanisms. "helminth therapy" is one strategy that harnesses these parasite-specific beneficial properties for the therapeutic treatment of autoimmune and allergic diseases. Although numerous experimental reports have documented the anti-autoimmune activities of parasitic infections and parasite-derived products, the underlying mechanisms remain insufficiently elucidated due to the significant diversity among parasite species and auto- immune conditions. Rheumatoid arthritis (RA) is one of the most prevalent autoimmune disorders, presenting a substantial opportunity for the therapeutic use of parasites as novel disease-modifying antirheumatic drugs (DMARDs). In this paper, we summarize the immunomodulatory properties of parasites, focusing on their anti- arthritic mechanisms, and discuss the potential of parasite-derived products for the treatment of RA.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Clélia Monchablon
    Henri Gondé
    Sophie Pouplin
    Rémi Varin
    Olivier Vittecoq
    Thierry Lequerré
    Clinical Rheumatology, 2020, 39 : 207 - 216
  • [32] The new British Society for Rheumatology disease modifying anti-rheumatic drugs guidelines
    Deighton, Chris
    Gadsby, Kate
    MUSCULOSKELETAL CARE, 2006, 4 (03) : 174 - 181
  • [33] Prevalence of coronavirus disease 2019 in rheumatic patients and evaluation of the effect of disease-modifying anti-rheumatic drugs
    Soroush Moradi
    Maryam Masoumi
    Somayeh Mohammadi
    Jamshid Vafaeimanesh
    Mohaddeseh Mohseni
    Hossein Mahdavi
    Armin Aryannejad
    Internal and Emergency Medicine, 2021, 16 : 919 - 923
  • [34] Prevalence of coronavirus disease 2019 in rheumatic patients and evaluation of the effect of disease-modifying anti-rheumatic drugs
    Moradi, Soroush
    Masoumi, Maryam
    Mohammadi, Somayeh
    Vafaeimanesh, Jamshid
    Mohseni, Mohaddeseh
    Mahdavi, Hossein
    Aryannejad, Armin
    INTERNAL AND EMERGENCY MEDICINE, 2021, 16 (04) : 919 - 923
  • [35] Use of biological disease-modifying anti-rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B
    King, L. K.
    Lee, A.
    Anandacoomarasamy, A.
    INTERNAL MEDICINE JOURNAL, 2012, 42 (05) : 523 - 531
  • [36] Effectiveness and Safety of Tacrolimus in Patients with Active Rheumatoid Arthritis with Inadequate Response to Disease-modifying Anti-rheumatic Drugs: The TREASURE Study
    Sheen, Dong Hyuk
    Hong, Seung Jae
    Lee, Sang Heon
    Lee, Hye Soon
    Chung, Won Tae
    Jiang, Hongsi
    Lee, Sungmin
    Yoo, Dae Hyun
    JOURNAL OF RHEUMATIC DISEASES, 2019, 26 (01): : 20 - 30
  • [37] Disease modifying anti-rheumatic drugs in juvenile idiopathic arthritis: striving for individualized therapy
    Funk, Ryan S.
    Becker, Mara L.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2016, 1 (01): : 53 - 68
  • [38] SARCOPENIA IN PATIENTS WITH RHEUMATOID ARTHRITIS ON THE TREATMENT WITH BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    Hasegawa, E.
    Ito, S.
    Kurosawa, Y.
    Taniguchi, S.
    Kobayashi, D.
    Abe, A.
    Otani, H.
    Nakazono, K.
    Murasawa, A.
    Narita, I.
    Ishikawa, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 985 - 985
  • [39] INFECTIOUS COMPLICATIONS AS A REASON FOR THE CANCELLATION OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Aronova, E.
    Gridneva, G.
    Kudryavtceva, A.
    Dydykina, I.
    Lukina, G.
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (SUPPL 1) : S250 - S250
  • [40] Development and evaluation of a poster to aid patient recall of disease modifying anti-rheumatic drugs
    Mitton, DL
    Douglas, KM
    Treharne, GJ
    Hale, ED
    Sandhu, R
    Erb, N
    Kitas, GD
    RHEUMATOLOGY, 2005, 44 : I157 - I157